** Analysts at Jefferies say several factors have the potential to lead to an upside for Integral Diagnostics' IDX.AX FY26 EBITDA estimates
** Brokerage says potential factors include upgrading of Partial to Full MRI Licences, which could drive MRI volumes, as well as lung cancer screening
** Jefferies maintains PT at A$3.60/shr and "buy" rating for stock
** IDX has 16 partial licences that will be upgraded — which should drive MRI volume, thereby increasing co's market share of MRIs by 183bp to 10.3% — brokerage
** All 13 analysts covering stock rate "buy" or higher; their median PT is A$3.10 — LSEG data
** Stock down 10% YTD, as of last close
(Reporting by Shivangi Lahiri in Bengaluru)
((shivangi.lahiri@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。